Hemodialysis: slightly beyond basics Dialysate calcium and magnesium concentrations

Size: px
Start display at page:

Download "Hemodialysis: slightly beyond basics Dialysate calcium and magnesium concentrations"

Transcription

1 Dialysate calcium and magnesium concentrations Stefan Farese Department of Nephrology Bürgerspital Solothurn

2 Dialysate calcium and magnesium concentrations Do we know the optimal concentrations? NO Short overview Pathophysiologic considerations Guidelines/recommendations (if available) Personal suggestions (after review of the literature)

3 Dialysate calcium concentrations over time Evolution of dialysate Ca concentrations over time aluminium PB PTH suppression Calcitriol, Ca PB Adynamic bone disease Vascular calcification Recommandation without hard data 1.25 mmol/l 1.75 mmol/l mmol/l mmol/l 1.25 mmol/l 1960s 1970s 1980s, 1990s 2000 Messa P., NDT 2013 Toussaint et al. Hemodial Int 2006

4 Estimation of calcium balance in renal failure Vitamin D deficiency, phosphate binders dialysate Ca vascular calcification Hyper /Hypopara renal failure From Messa P. NDT 2013

5 Dialysate calcium concentrations hyperparathyreoidism increase Ca What is your goal? Treatment of... hypoparathyreoidism and adynamic bone disease hyper or hypocalciemia hemodynamic stability during dialysis decrease Ca decrease /increase Ca increase Ca hyperphosphatemia with calcium/noncalcium phosphate binders, calcitriol decrease /increase Ca

6 Dialysate calcium concentrations Ca dialysate 1.5 mmol/l Neutral Ca balance** Ca dialysate 1.75 mmol/l Positive Ca balance** Ca dialysate 1.25 mmol/l Negative Ca balance**..however, Ca transfer during dialysis depends also on the Ca gradient between serum and dialysate concentration and total calcium balance as well on vitamin D and Ca binder use Toussaint et al. Hemodial Int 2006

7 Dialysate calcium concentrations acute effects Hemodynamic stability on dialysis Intradialytic hypotension Preventive effect of high dca (1.75mmol/l) Increased cardiac contractility (+ increased peripheral resistence) synergistic effect with high dmg and high dhco 3 Maynard et al. Ann Intern Med 1986 Heinrich et al. NEJM 1984 Gabutti et al. NDT 2009 Gabutti et al. NDT 2009 Toussaint et al. Hemodila Int 2006

8 Dialysate calcium concentrations acute effects Hemodynamic stability on dialysis Calcium overload with chronic dca 1.75mmol/l?? dca profiling (n=18) dca 1.25 for 4h vs dca 1.25 for 2h then 1.75 for 2h vs dca 1.5 for 4h n=8 9 treatments with 1.25 vs 9 with 1.25/1.75 dca in random order Reduced intradialytic events Kyriazis et al. Kidney Int 2002

9 Dialysate calcium concentrations acute effects Cardiac arrhythmias N= HD patients, N=510 witnessed cardiac arrest vs 1560 matched controls Risk probably potentiated with concomitant hypokaliemia (or large dialysate serum K + gradient) Pun et al. CJASN 2013 Severi et al. NDT 2008

10 Dialysate calcium concentrations chronic effects Effects on bone Low turn over bone disease PTH (!) Reduction of dca from 1.75 to 1.25 mmol/l or from 1.5 to 1.25mmol/l PTH (+ others) Fiedler et al. Nephron Clin Pract 2004 Hamano et al. Bone 2005 High turn over bone disease Suppression of PTH with higher dca (1.75 mmol/l) Toussaint et al. Hemodial Int 2006

11 Dialysate calcium concentrations chronic effects Effects on vessels? Higher dca aortic puls wave velocity (=vascular stiffness) over time (6 mts) Hypercalciemia..however Acute effects of dca variations on PWV observed LeBoeuf et al. NDT 2011 Charitaki et al. BMC Nephrology 2013 LeBoeuf et al. NDT 2011 Kim et al. Korean J Int Med 2011 Davenport et al. Blood Purif 2010 vascular stiffness = vascular calcification??

12 Summary dialysate calcium concentrations Dialysate Calcium Advantages Disadvantages Low ( mmol/l) Risk for Hypercalciemia Potential for negative Ca balance and PTH Greater use of Vitamin D and Ca containing phosphate binders allowed Intra dialytic hypotension Benefit in adynamic bones Cardiac arrhythmias High ( mmol/l) hemodynamic stability Risk of hypercalciemia Benefit on bone protection in nocturnal HD Limited use of vitamin D and calcium based binders PTH Risk of vascular calcification adapted from Toussaint et al. Hemodial Int 2006

13 Dialysate magnesium Magnesium in ESRD Vascular tone ( ) Heart contractility ( ) Arrhythmias ( ) LV Hypertrophy ( ) PTH ( ) Osteoporosis ( ) Insulin Resistance ( ) Inflammation ( ) Vascular calcification ( ) Mortality ( )

14 Dialysate Magnesium: Mg kinetics during high efficiency dialysis HD Session with 0 mmol/l Mg removal 486 +/ 44mg HD Session with 0.25 mmol/l Mg removal 306 +/ 69 mg HD Session with 0.75 mmol/l Mg removal 56 +/ 50m Plasma Mg concentrations constant with 0.75mmol/l

15 Dialysate Magnesium: acute effects Blood pressure and myocardial contractility n=8, in randomized order, 4 h HD Group I Mg 0.75, Ca 1.75 Group II Mg 0.25, Ca 1.75 Group III Mg 0.75, Ca 1.25 Group IV Mg 0.25, Ca 1.25 Group I and III: smg +2% Low Ca, low Mg Group II and IV:s Mg 35% Group IV: CI, stroke Index, MAP Kyriazis et al. Kidney Int 2004

16 Dialysate Magnesium: acute effects Blood pressure and myocardial contractility n=14 (ca 1.25mmol/l) 4 weeks with 0.5mmol/l 4 weeks with 0.25 mmol/l 4 weeks with 0.75 mmol/l dmg 0.75mmol/l significant reduction in intradialytic morbidity and improved BD stability Intradialytic changes of serum Mg correlation with hypotensive episodes Elsharkawy et al. Hemodial Int 2006 Kyriazis et al. Kidney Int 2004

17 Dialysate magnesium: acute effects Muscle cramps n=15 Switch from 0.75 to 0 mmol/l dmg + oral MgCO 3 for 2 weeks and dmg 0.25 mmol/l for 2 weeks Severe muscle cramps (n=8) not associated with changes in blood pressure Immediate relief after switch to 0.75 mmol/l and dmg oral Mg CO 3 mmol/l for 2 weeks Well tolerated Kelber et al. AJKD 1994

18 Dialysate magnesium: which one to choose? Optimal dmg concentration 0.75 mmol/l for blood pressure and muscle cramps (...if no Mg phosphate binder is used) Information from guidelines? EBPG on HD (2007) in patients with frequent episodes of IHD, low (0.25mmol/l) dmg should be avoided, especially in in combination with low calcium dialysate CARI (2000) mmol/l will maintain normomagnesemia...but levels in some case may have to be individualised

19 Dialysate magnesium: chronic effects Evidence from animal studies supporting use of higher dmg Mg supplemented diet prevents/retards VC Gorgels et al. J Mol Med 2010 Mg CO3 phosphate binder vs Lanthanum prevents VC Li et al. Clin Transl Sci 2009 by unclear, probably multiple mechanisms (direct inhibition of hydroxyapatite formation, cellular effects, expression of anti calcification proteins...) Massy et al. Clin Kidney J 2012

20 Dialysate Magnesium: chronic effects Evidence from human studies supporting the use of higher dmg Tissue calcification Low serum Mg in HD patients vascular calcification (VC) (independent of Ca, Ph, and PTH) Ishimura et al. Clin Nephrol 2007 Mitral annular calcifications Tzanakis et al. NDT 1997 Increased carotid intima media thickness oral Mg supplementation reduces thickness Turgut et al. Int Urol Nephrol 2008 Dietary Mg (MgCO 3 / Mg citrate) supplementation prevents/retards (VC) Turgut et al. Int Urol Nephrol 2008 Spiegel et al. Hemodial Int 2009

21 Dialysate magnesium: chronic effects Evidence from human studies supporting the use of higher dmg Outcome n= 515 HD patients, mean follow up 51 months, observational prospective Higher Mg group >1.1.4mmol/l Lower Mg group < 1.14mmol/l Serum Mg at 0 and 1 year correlates strongly Serum Mg = independent significant predictor overall mortality (OR 0.48 per 0.41 mmol/l Mg) Ishimura et al. Magnes Res 2007

22 Dialysate magnesium: chronic effects Evidence from human studies supporting the use of higher dmg Outcome n= (FMC North America facilities) retrospecitve Results Compared to mid normal values ( mmol/l) drop of hazard ratio at smg 0.95 mmol/l to as low as 0.68 at smg > 1.15 mmol/l Linear trend lower mortality with increasing serum Mg concentrations Lacson et al. Poster at the Renal Week 2009 in San Diego, US Passlick Deetjen, oral presentation at the ERA/EDTA Congress 2012 in Munich, Germany

23 Dialysate magnesium: chronic effects Evidence from human studies supportin the use of higher dmg Effects on serum calcification propensity JASN 2012 N =45 chronic HD patients, crossover design Assessment of calcification propensity with a 0.5mmol/l dmg vs 0.75mmol/l dmg JASN 2013 Preliminary Results 0.75mmol/l dmg improves calcification propensity in serum of HD Patients under preparation for publication Effect on outcome?

24 Dialysate calcium: Summary Optimal dca concentration Guidelines (KDOQI): mmol/l Compromise between the need for personal suggestion (after review of literature) cardiovascular stability during HD the goal to maintain normal (?) bone turnover and tissue mineralization

25 Dialysate magnesium: Summary Optimal dmg concentration No or few comments in major guidelines dmg 0.75 (or higher?) favorable for personal suggestion (after review of literature) cardiovascular stability during dialysis probable positive effect on vascular calcification no major side effects reported (without concomitant use of Mgphosphate binders)

2017 KDIGO Guidelines Update

2017 KDIGO Guidelines Update 2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation

More information

HTA ET DIALYSE DR ALAIN GUERIN

HTA ET DIALYSE DR ALAIN GUERIN HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age

More information

OPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura

OPEN.  Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance

More information

BONE AND MINERAL METABOLISM in the PD PATIENT

BONE AND MINERAL METABOLISM in the PD PATIENT BONE AND MINERAL METABOLISM in the PD PATIENT John Burkart, MD Professor of Medicine/Nephrology Wake Forest University Baptist Medical Center Chief Medical Officer Health Systems Management Maria V. DeVita,

More information

Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis

Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu

More information

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs

More information

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD

More information

Guidelines and new evidence on CKD - MBD treatment

Guidelines and new evidence on CKD - MBD treatment Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,

More information

02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.

02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement

More information

Cardiovascular Mortality: General Population vs ESRD Dialysis Patients

Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Cardiovascular Mortality: General Population vs ESRD Dialysis Patients Annual CVD Mortality (%) 100 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age (years) GP Male GP Female GP Black GP

More information

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among

More information

TO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT?

TO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT? TO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT? Rana G. Rizk, PhD, MPH, LD Maastricht University, The Netherlands November, 2017 Learning objectives Review the evidence behind benefits and concerns

More information

Treatment Options for Chronic Kidney

Treatment Options for Chronic Kidney Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition

More information

Ana Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto

Ana Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto Ana Paula Bernardo CHP Hospital de Santo António ICBAS/ Universidade do Porto Clinical relevance of hyperphosphatemia Phosphate handling in dialysis patients Phosphate kinetics in PD peritoneal phosphate

More information

Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano

Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale. Maurizio Gallieni Università degli Studi di Milano Ipovitaminosi D e metabolismo calcio-fosforo in dialisi peritoneale Maurizio Gallieni Università degli Studi di Milano G Ital Nefrol 2018 - ISSN 1724-5990 Nutrients 2017, 9, 328 Vitamin D deficiency (

More information

Therapeutic golas in the treatment of CKD-MBD

Therapeutic golas in the treatment of CKD-MBD Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral

More information

Month/Year of Review: September 2012 Date of Last Review: September 2010

Month/Year of Review: September 2012 Date of Last Review: September 2010 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Secondary Hyperparathyroidism: Where are we now?

Secondary Hyperparathyroidism: Where are we now? Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused

More information

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea

More information

KDIGO. CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke

KDIGO. CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke CKD- MBD: Is the Term S2ll Jus2fied? Tilman B. Drüeke Unité 1088 de l Inserm UFR de Médecine et de Pharmacie Jules Verne University of Picardie Amiens, France Poten2al conflicts of interest Research support:

More information

Cinacalcet treatment in advanced CKD - is it justified?

Cinacalcet treatment in advanced CKD - is it justified? Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to

More information

La relation dialyse et nutrition

La relation dialyse et nutrition Nutrition en dialyse : controverses La relation dialyse et nutrition Charles Chazot, MD NephroCare Tassin-Charcot Sainte Foy Les Lyon, France HEMO study lessons (1) Dose Body weight flux Rocco, Kidney

More information

IMPLEMENTATION OF THE CKD-MBD PRACTICE. Goce Spasovski, R. Macedonia

IMPLEMENTATION OF THE CKD-MBD PRACTICE. Goce Spasovski, R. Macedonia IMPLEMENTATION OF THE CKD-MBD GUIDELINES Introduction INTO CLINICAL to Renagel PRACTICE Goce Spasovski, R. Macedonia Antalya, Turkey, September 16 2012 Session Objectives Guidelines needs and controversy

More information

The goal of dialysis for patients with chronic renal failure is to

The goal of dialysis for patients with chronic renal failure is to Dialysate Composition in Hemodialysis and Peritoneal Dialysis Biff F. Palmer The goal of dialysis for patients with chronic renal failure is to restore the composition of the body s fluid environment toward

More information

Timing, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement

Timing, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement Timing, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement Prof. Dr. Achim Jörres Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum

More information

Treatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia

Treatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia Budapest, August 29, 2011 Session Objectives Definition of the problem of CKD-MBD

More information

THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION

THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION Mario Cozzolino, MD, PhD, Fellow of the European Renal Association Department of Health Sciences University of Milan Renal Division & Laboratory

More information

Hemodiafiltration: principles and advantages over conventional HD. Rukshana Shroff Great Ormond Street Hospital for Children London, UK

Hemodiafiltration: principles and advantages over conventional HD. Rukshana Shroff Great Ormond Street Hospital for Children London, UK Hemodiafiltration: principles and advantages over conventional HD Rukshana Shroff Great Ormond Street Hospital for Children London, UK Effectiveness of RRT modalities Mcfarlane, Seminars in dialysis, 2009

More information

New biological targets for CKD- MBD: From the KDOQI to the

New biological targets for CKD- MBD: From the KDOQI to the New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr

More information

HEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS 1.0 PRACTICE CONSIDERATIONS 2.0 CURRENT LITERATURE REVIEW

HEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS 1.0 PRACTICE CONSIDERATIONS 2.0 CURRENT LITERATURE REVIEW HEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS This document was prepared at the request of the BC Hemodialysis Committee to provide a brief overview of the literature and to identify

More information

( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes

( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes ..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol

More information

Level 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor

Level 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor chapter 4.1 http://www.kidney-international.org & 2009 KDIGO Chapter 4.1: Treatment of CKD MBD targeted at lowering high serum phosphorus and maintaining serum calcium ; doi:10.1038/ki.2009.192 Grade for

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES

More information

Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients

Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients Ca, Phos and Vitamin D Metabolism in Pre-Dialysis Patients A. WADGYMAR, MD Credit Valley Hospital, Mississauga, Ontario, Canada. June 1, 2007 1 Case: 22 y/o referred to Renal Clinic Case: A.M. 29 y/o Man

More information

Cardiovascular Complications of Dialysis In Children. Why is this important? Why is this Important? 01/26/2017. Dr Daljit Hothi

Cardiovascular Complications of Dialysis In Children. Why is this important? Why is this Important? 01/26/2017. Dr Daljit Hothi Cardiovascular Complications of Dialysis In Children Dr Daljit Hothi Great Ormond Street Hospital, London Why is this important? 100 90 Why is this Important? Long Term Survival of Childhood Onset ESRD

More information

Left ventricular hypertrophy: why does it happen?

Left ventricular hypertrophy: why does it happen? Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,

More information

Management of CKD. Goce Spasovski, R. Macedonia

Management of CKD. Goce Spasovski, R. Macedonia Management of CKD complications Introduction Bone disease to Renagel Goce Spasovski, R. Macedonia Istanbul, June 4, 2011 Session Objectives - Mineral and Bone Disorders (MBD) Bone disease a part of CKD

More information

Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis

Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and

More information

Original epidemiologic studies 1 have suggested that approximately

Original epidemiologic studies 1 have suggested that approximately Factors for Increased Morbidity and Mortality in Uremia: Hyperphosphatemia Nathan W. Levin, Frank A. Gotch, and Martin K. Kuhlmann Hyperphosphatemia is a metabolic abnormality present in the majority of

More information

KDOQI Guidelines. Overview. Predicting Successful Fistula Maturation Warren Gasper MD UCSF Vascular Surgery Fellow 2011 UCSF Vascular Symposium

KDOQI Guidelines. Overview. Predicting Successful Fistula Maturation Warren Gasper MD UCSF Vascular Surgery Fellow 2011 UCSF Vascular Symposium DISCLOSURES: NONE Predicting Successful Fistula Maturation Warren Gasper MD UCSF Vascular Surgery Fellow 2011 UCSF Vascular Symposium KDOQI Guidelines AV fistulas have better outcomes than grafts or catheters

More information

Effects of Lowering Dialysate Calcium Concentration on Mineral Metabolism and Hemodynamic Parameters in Hemodialysis Patients

Effects of Lowering Dialysate Calcium Concentration on Mineral Metabolism and Hemodynamic Parameters in Hemodialysis Patients DIALYSIS Effects of Lowering Dialysate Calcium Concentration on Mineral Metabolism and Hemodynamic Parameters in Hemodialysis Patients Ahmed Alayoud, 1 Driss El Kabbaj, 2 Mohammed Benyahia, 2 Mohammed

More information

CKD-MBD CKD mineral bone disorder

CKD-MBD CKD mineral bone disorder CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature

More information

The Parsabiv Beginner s Book

The Parsabiv Beginner s Book The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism

More information

Setting the standard

Setting the standard SCLEROSTIN in NEPHROLOGY MOST REFERENCED OPTIMIZED FOR CLINICAL SAMPLES Setting the standard for clinical research. SCLEROSTIN A BONE-RELATED PROTEIN URINE PROTOCOL AVAILABLE Sclerostin ELISA - Assay Characteristics

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL

More information

KDIGO LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE

KDIGO LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE LESSONS LEARNED FROM NEPHROLOGY TRIALS WITH RESPECT TO HEART FAILURE Dr. Christopher T Chan Director Division of Nephrology University Health Network Professor of Medicine University of Toronto Disclosure

More information

Calcium Management for Patients Receiving Extended Duration Hemodialysis

Calcium Management for Patients Receiving Extended Duration Hemodialysis Calcium Management for Patients Receiving Extended Duration Hemodialysis Created November 2017; Updated March 2018 Approved by the BCPRA Home Hemodialysis Committee Table of Contents 1.0 Practice Standard...1

More information

Life Science Journal 2014;11(10)

Life Science Journal 2014;11(10) Comparison between two dialysate calcium concentrations on parathormone level in hemodialysis patients with and without valvular calcification Dawlat Belal 1, Bahaa Zayed 1, Eglal Kenawy 2, Malak Nabil

More information

Macro- and Micronutrient Homeostasis in the Setting of Chronic Kidney Disease. T. Alp Ikizler, MD Vanderbilt University Medical Center

Macro- and Micronutrient Homeostasis in the Setting of Chronic Kidney Disease. T. Alp Ikizler, MD Vanderbilt University Medical Center Macro- and Micronutrient Homeostasis in the Setting of Chronic Kidney Disease T. Alp Ikizler, MD Vanderbilt University Medical Center Nutrition and Chronic Kidney Disease What is the disease itself and

More information

Calcimimetic agents, vascular calcification prevention 276 Calcium parathyroid hormone regulation Subject Index 357

Calcimimetic agents, vascular calcification prevention 276 Calcium parathyroid hormone regulation Subject Index 357 Subject Index Advanced glycation end products (AGEs) atherosclerosis role 168 dietary sources 202, 203 formation 168 platelet phosphatidylserine externalization induction 171, 172 signaling 173 toxicity

More information

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Nutrition and Dietetic Service Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Authors Hilary Mathieson, Renal Dietitian Paul McKeveney, Consultant Nephrologist

More information

Structural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak

Structural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak Structural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak Kerstin Amann Nephropathology, Dept. of Pathology, University of Erlangen-Nürnberg Krankenhausstr. 8-10 91054

More information

Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi

Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi Mario Cozzolino, MD, PhD, FERA Dipartimento di Scienze della Salute Università di Milano UO Nefrologia e Dialisi Laboratorio

More information

Advances in Peritoneal Dialysis, Vol. 29, 2013

Advances in Peritoneal Dialysis, Vol. 29, 2013 Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate

More information

Sodium elimination and dialysate sodium. How much? Does it matter?

Sodium elimination and dialysate sodium. How much? Does it matter? Sodium elimination and dialysate sodium How much? Does it matter? A. Bock Nephrologie Dialysis visit Aarau 3.12.2013 90 kg dialysis patient: 5 kg over dry weight Recent dyspnea. Minimal leg edema RBV in

More information

Month/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )

Month/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro ) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

A new era in phosphate binder therapy: What are the options?

A new era in phosphate binder therapy: What are the options? http://www.kidney-international.org & 2006 International Society of Nephrology A new era in phosphate binder therapy: What are the options? IB Salusky 1 1 Department of Pediatrics, David Geffen School

More information

CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism

CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism Pieter Evenepoel Nephrology, Dialysis, and Transplantation University Hospitals Leuven April 2017, FMC Herbeumont Disclosures Research support:

More information

Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University

Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Hypertension in Hemodialysis Patient Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Mechanism of HTN in HD patients Volume-dependent HTN ECV expansion. Volume-independent HTN

More information

PREVALENCE AND TYPES OF INTRA-DIALYTIC COMPLICATIONS IN PATIENTS DIALYSING AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL

PREVALENCE AND TYPES OF INTRA-DIALYTIC COMPLICATIONS IN PATIENTS DIALYSING AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL PREVALENCE AND TYPES OF INTRA-DIALYTIC COMPLICATIONS IN PATIENTS DIALYSING AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL ADEJUMO OA, OLOKOR AB, IYAWE IO, OKAKA EI, UNUIGBE EI, OJOGWU LI Presented at Nigerian

More information

chapter 1 & 2009 KDIGO

chapter 1 & 2009 KDIGO http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3

More information

Dialysis: the long case

Dialysis: the long case Dialysis: the long case Prof Mark Brown St George Public Hospital, Kogarah The case SD 1. What significant things have been omitted from the history? 2. Physical findings 70 RTA; mitral regurg murmur;

More information

Use of magnesium as a drug in chronic kidney disease

Use of magnesium as a drug in chronic kidney disease Clin Kidney J (2012) 5[Suppl 1]: i62 i70 doi: 10.1093/ndtplus/sfr168 Use of magnesium as a drug in chronic kidney disease Alastair J. Hutchison 1 and Martin Wilkie 2 1 University of Manchester and Manchester

More information

Achieving Equilibrium in ESRD Patients

Achieving Equilibrium in ESRD Patients Achieving Equilibrium in ESRD Patients -Marc Richards MD -South Florida Kidney Disease and HTN Specialists -Chief of Medicine, BRRH -BRRH Grand Rounds: April 18 th, 2017 Outline Dialysis prescription Adequacy

More information

On Referral to our Unit

On Referral to our Unit Case Presentation By Samah Ibrahim Abdel Meguid Idris, MD Internal Medicine & Nephrology Consultant Head of Hemodialysis Unit Ahmed Maher Hospital, Alexandria Patient Data MEA 27-year-old male patient

More information

Velphoro (sucroferric oxyhydroxide)

Velphoro (sucroferric oxyhydroxide) STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney

More information

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD

More information

Bone Disorders in CKD

Bone Disorders in CKD Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis

More information

The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.

The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &

More information

Secondary hyperparathyroidism in dialysis patients

Secondary hyperparathyroidism in dialysis patients Secondary hyperparathyroidism in dialysis patients ( a critical approach of pharmacological treatments) Dominique JOLY Néphrologie Hôpital NECKER, Paris DFG Finn WF. J Am Soc Nephrol. 24;15:271A. Ca ++

More information

CKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology

CKD and CVD. Jamal Salameh, MD, FACP, FASN First Coast Nephrology CKD and CVD Jamal Salameh, MD, FACP, FASN First Coast Nephrology An Epidemic of Kidney Disease Prevalence CKD stages 1-4 10% 1988-94 13% 1999-2004 Coresh, JAMA 298:2038, 2007 Stage 5: GFR

More information

Nutrition and Renal Disease Update

Nutrition and Renal Disease Update Nutrition and Renal Disease Update Denis FOUQUE Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France What have we learned? 1. Chronic kidney disease:

More information

Epidemiology, Diagnostic and treatment for Protein Energy Wasting in Dialysis

Epidemiology, Diagnostic and treatment for Protein Energy Wasting in Dialysis Epidemiology, Diagnostic and treatment for Protein Energy Wasting in Dialysis Pr Denis FOUQUE Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France ESRD

More information

Normal kidneys filter large amounts of organic

Normal kidneys filter large amounts of organic ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),

More information

Hemodynamic Instability in HD patients: Dialysis Hypotension Prof Ali BAŞÇI MD FERA Ege University Medical School

Hemodynamic Instability in HD patients: Dialysis Hypotension Prof Ali BAŞÇI MD FERA Ege University Medical School Hemodynamic Instability in HD patients: Dialysis Hypotension Prof Ali BAŞÇI MD FERA Ege University Medical School Relationship between blood pressure and mortality in patients treated with volume control

More information

Outline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010

Outline. The Role of Vitamin D in CKD. Essential Role of Vitamin D. Mechanism of Action of Vit D. Mechanism of Action of Vit D 7/16/2010 Outline The Role of Vitamin D in CKD Priscilla How, Pharm.D., BCPS Assistant Professor National University of Singapore Principal Clinical Pharmacist National University Hospital (Pharmacy and Nephrology,

More information

Pr Denis FOUQUE. Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France

Pr Denis FOUQUE. Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France Pr Denis FOUQUE Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France Observatoire Phosphocalcique, January 2011 1200 36.1 ± 5.0 g/l 1050 900 PEW

More information

Stefanos K. Roumeliotis. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece. Stefanos K.

Stefanos K. Roumeliotis. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece. Stefanos K. Department of Nephrology, Medical School Democritus University of Thrace, Alexandroupolis, Greece Passive, degenerative accumulation process of Ca ++ /P +++ without treatment options Active, complex, condition:

More information

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker

More information

Diagnosis is it really Heart Failure?

Diagnosis is it really Heart Failure? ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University

More information

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker

More information

Research Article Magnesium and Muscle Cramps in End Stage Renal Disease Patients on Chronic Hemodialysis

Research Article Magnesium and Muscle Cramps in End Stage Renal Disease Patients on Chronic Hemodialysis Advances in Nephrology, Article ID 681969, 6 pages http://dx.doi.org/10.1155/2014/681969 Research Article Magnesium and Muscle Cramps in End Stage Renal Disease Patients on Chronic Hemodialysis Patrick

More information

Therapeutic Challenges in CKD & ESRD: Managing Acid-base & electrolytes. No financial disclosure

Therapeutic Challenges in CKD & ESRD: Managing Acid-base & electrolytes. No financial disclosure Therapeutic Challenges in CKD & ESRD: Managing Acid-base & electrolytes Qi Qian, MD, FASN Mayo Clinic, College of Medicine No financial disclosure 2016 MFMER 3563115-1 ü - ü - 1. Acidosis 2. Hyperkalemia

More information

The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD

The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD Jess Tower MS RD LD 3/18/19 Children s Mercy Hospital jdtower@cmh.edu 816 460 1067 Disclosures Nothing to disclose 1 How

More information

Renal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD

Renal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral

More information

Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis

Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis Investigations for Disorders of Calcium, Phosphate and Magnesium Homeostasis Tutorial for Specialist Portfolio Biomedical Scientists 03/02/2014 Dr Petros Kampanis Clinical Scientist 1. Calcium Most abundant

More information

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE

More information

Drugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia

Drugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia NSW Therapeutic Advisory Group Level 5, 376 Victoria Street PO Box 766 Darlinghurst NSW 2010 Phone: 61 2 8382 2852 Fax: 61 2 8382 3529 Email: nswtag@stvincents.com.au www.nswtag.org.au Drugs for the treatment

More information

Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1

Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1 Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1 Not an actual Parsabiv vial. The displayed vial is for illustrative

More information

Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients

Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Author's response to reviews Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Authors: Da Shang (sdshangda@163.com) Qionghong

More information

A team s approach to QOL in CKD patients

A team s approach to QOL in CKD patients A team s approach to QOL in CKD patients Edwin Fong MD FRCPC Which Team? Beauty Symmetry Beauty defined Suntanned Narrower face Less fat Fuller lips Bigger distance of eyes Darker eye brows Higher cheek

More information

Dialysis in frail and Elderly

Dialysis in frail and Elderly Dialysis in frail and Elderly Dr Shibu Jacob, Assistant Professor, Christian Medical College, Vellore. ISHDCON April 2,2017 Complications during dialysis and soon after? How to minimise these? Should

More information

JOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY

JOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to

More information

CARE FOR CHRONIC RENAL PATIENTS ROLE OF MULTIDISCIPLINARY APPROACH ÁGNES HARIS MD PHD, ST. MARGIT HOSPITAL, BUDAPEST BUDAPEST NEPHROLOGY SCHOOL, 2017

CARE FOR CHRONIC RENAL PATIENTS ROLE OF MULTIDISCIPLINARY APPROACH ÁGNES HARIS MD PHD, ST. MARGIT HOSPITAL, BUDAPEST BUDAPEST NEPHROLOGY SCHOOL, 2017 CARE FOR CHRONIC RENAL PATIENTS ROLE OF MULTIDISCIPLINARY APPROACH ÁGNES HARIS MD PHD, ST. MARGIT HOSPITAL, BUDAPEST BUDAPEST NEPHROLOGY SCHOOL, 2017 RENEGOTIATING LIFE WITH CHRONIC KIDNEY DISEASE CONSTANTINI

More information

Do higher dialysate calcium concentrations increase vascular stiffness in haemodialysis patients as measured by aortic pulse wave velocity?

Do higher dialysate calcium concentrations increase vascular stiffness in haemodialysis patients as measured by aortic pulse wave velocity? Charitaki and Davenport BMC Nephrology 2013, 14:189 RESEARCH ARTICLE Open Access Do higher dialysate calcium concentrations increase vascular stiffness in haemodialysis patients as measured by aortic pulse

More information

Control of hyperphosphatemia is a major goal in patients

Control of hyperphosphatemia is a major goal in patients ORIGINAL ARTICLES Phosphorus Clearance Using Two Hemodialyzers Placed in Parallel Mitchell H. Rosner, 1,2 Allen Helmandollar, 1 Ryan Evans, 1 Emaad Abdel-Rahman 1 Division of Nephrology, 1 University of

More information

End stage renal disease and Protein Energy wasting

End stage renal disease and Protein Energy wasting End stage renal disease and Protein Energy wasting Dr Goh Heong Keong MBBS,MRCP(UK) www.passpaces.com/kidney.htm Introduction Chronic kidney disease- increasing health burden in many countries. The estimated

More information

The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure

The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,

More information

Pediatric CKD-MBD: pathophysiology and management

Pediatric CKD-MBD: pathophysiology and management Pediatric CKD-MBD: pathophysiology and management Justine Bacchetta, MD, PhD Reference Center for Rare Renal Diseases Reference Center for Rare Diseases of Calcium and Phosphate Bron, France Overview of

More information

TRANSPARENCY COMMITTEE OPINION. 22 July 2009

TRANSPARENCY COMMITTEE OPINION. 22 July 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL

More information